ZebiAI Therapeutics, Inc. and X‑Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery
New venture capital-backed artificial intelligence company to utilize X-Chemβs leading DNA encoded library screening service WALTHAM, Mass. β ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately held companies, today announced a multiyear service and license agreement. The agreement provides ZebiAI access to X-Chemβs proprietary DNA Encoded Library technology (DEXβ’) for the discovery of novel small molecules to support ZebiAIβs Chemome Initiative β the identification of probe molecules for novel targets β and drug candidate identification to build upon discoveries from the Chemome effort. The collaboration additionally marks the establishment of ZebiAI Therapeutics alongside a funding round led by Anterra Capital.
XβChem Transitions Executives into New Roles, Appoints New Chief Executive Officer
WALTHAM, Mass.; Jan. 4, 2024 (Business Wire) β X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today...
XD3
Partner with X-Chem to experience cutting-edge small molecule discovery from the pioneers of DEL screening. Our scientists blend the power...
Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases
Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) β Servier, a global pharmaceutical Group and X-Chem, Inc., a privately...
X‑Chem spin-off X-Biotix Therapeutics Completes $7 million Series A Financing
WALTHAM, Mass. April 24, 2018 β Small molecule drug discovery specialist X-Chem, Inc. (XChem) today announced that its spin-out company X-Biotix Therapeutics, Inc. (X-Biotix) has secured $7 million in a Series A financing from a group of private investors. X-Biotix, launched in 2017 out of X-Chem by Ramani Varanasi, Ph.D. and faculty members in the Department of Microbiology and Immunobiology at Harvard Medical School, plans to use the financing to advance its pipeline of novel antibiotics targeting Gram-negative bacteria. The company leverages the research of its scientific founders in essential biological pathways in bacteria and X-Chemβs DNA-encoded small molecule discovery platform.
Evotec and X‑Chem Collaborate to Accelerate Early-Stage Drug Discovery
WALTHAM, Mass.; Sept. 5, 2024 β Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader...
X‑Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range
Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSynβs Founder...
ALK-AbellΓ³ and X‑Chem Announce Drug Discovery Collaboration
WALTHAM, Mass. β February 5, 2019 - X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with ALK-AbellΓ³ A/S (ALK), a Danish pharmaceutical company focused on the prevention and treatment of allergies. This collaboration will focus on the discovery of small molecule drug products to treat broad ranging allergies.